TL;DR
For each dimension where one drug clearly wins, we name the winner. When the answer is "depends on your situation," the verdict text below the table explains why.
| Dimension | What the data says | Winner |
|---|---|---|
| Active ingredient | Semaglutide (Ozempic) vs tirzepatide (Mounjaro) | Mounjaro |
| Mechanism | GLP-1 only (Ozempic) vs dual GLP-1/GIP (Mounjaro) | Mounjaro |
| HbA1c reduction in trial | Ozempic -1.4% (1.0mg) vs Mounjaro -2.3% (SURPASS-2, 15mg) | Mounjaro |
| Weight loss as secondary endpoint | Ozempic ~5% (SUSTAIN-6, 1.0mg) vs Mounjaro 13.1% (SURPASS-2, 15mg); different trials | Mounjaro |
| Real-world track record | Ozempic launched 2017; Mounjaro launched 2022 | Ozempic |
| Insurance coverage breadth | Both broadly covered for diabetes; Ozempic on more formularies | Ozempic |
Verdict
For type 2 diabetes patients optimizing for HbA1c control and weight loss, Mounjaro's dual-agonist mechanism is more effective per the SURPASS trials. For patients prioritizing the longest safety record or whose insurance places Ozempic on a lower formulary tier, Ozempic remains a strong option. For patients seeking weight loss without diabetes, neither is the right answer; Wegovy or Zepbound carries the indication.
Trial efficacy compared
The headline numbers are not from the same study, so direct comparison is approximate. The SURMOUNT-5 trial directly compared tirzepatide to semaglutide at obesity doses and found tirzepatide produced greater weight loss (20.2% vs 13.7% mean over 72 weeks), validating the cross-trial signal.
| Ozempic | Mounjaro | |
|---|---|---|
| Registration trial | SUSTAIN-6 (NEJM, 2016) | SURPASS-2 (NEJM, 2021) |
| Duration | 104 weeks | 40 weeks |
| Mean weight loss (max dose) | 5% | 13.1% |
| Effect vs comparator | 4.4 pp vs placebo | 6.4 pp vs semaglutide 1mg |
| Patients losing ≥5% | n/a | 86% |
| Patients losing ≥15% | n/a | 40% |
2026 cash-pay cost compared
NovoCare for Ozempic is the direct cash channel that runs well below the retail pharmacy cash price; the other has no public manufacturer cash-pay channel for weight loss. Telehealth programs add a membership fee on top of medication cost.
| Channel | Ozempic | Mounjaro |
|---|---|---|
| Retail cash | $998/mo | $1,069/mo |
| Manufacturer DTC | $199-$349/mo via NovoCare (dose-tier dependent) | Not publicly available for cash-pay; LillyDirect handles Zepbound for weight loss |
| With insurance + PA | $25-$50/mo with diabetes diagnosis and prior authorization | $25-$50/mo with diabetes diagnosis and prior authorization |
| Compounded | $175-$199/mo via 503A pharmacies (same active ingredient as Wegovy) | $199-$349/mo via 503A pharmacies (same active ingredient as Zepbound) |
When to choose Ozempic
Choose Ozempic if: (1) your insurance covers Ozempic on a lower tier than Mounjaro; (2) you've been stable on Ozempic and have no reason to switch; (3) you tolerate semaglutide better than tirzepatide (real-world tolerance varies); (4) you prefer the drug with a longer post-marketing safety record at obesity-treatment doses.
When to choose Mounjaro
Choose Mounjaro if: (1) Ozempic at 1.0mg or 2.0mg has not produced sufficient HbA1c reduction; (2) you want the more effective option for weight loss as a secondary benefit; (3) your prescriber is using SURPASS trial data to guide therapy escalation. The dual GLP-1/GIP mechanism produces larger effects across both endpoints in head-to-head and cross-trial comparisons.
Programs that prescribe each
Some visit links earn us a commission.
Top Ozempic programs
Top Mounjaro programs
FAQ
Is Mounjaro stronger than Ozempic?
Are they both off-label for weight loss?
Can I switch from Ozempic to Mounjaro?
Which has more side effects?
Read the full drug profiles
Editorial disclosure
GLP Chart is an editorial comparison site. We do not dispense, prescribe or fulfill medications. Trial data is from the cited NEJM publications. Pricing reflects publicly verified rates as of June 22. Talk to a licensed clinician about which medication is appropriate for you.
